China Cord Blood Corporation Announces Completion of Warrant Exchange Successfully Removes 13.0 Million Warrants from Capital Structure PR Newswire
HONG KONG, Dec. 13, 2010
HONG KONG, Dec. 13, 2010 /PRNewswire-Asia-FirstCall/ - China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company"), the first and largest cord blood banking operator in China, today announced the completion of its previously announced warrant exchange offer, which allowed warrant holders to receive one ordinary share for every eight warrants outstanding. The Company issued 1,627,518 ordinary shares, equivalent to 2.2% of shares outstanding as of December 10, 2010, in exchange for 13,020,236 warrants. Investors participating in the warrant exchange offer are subject to a 45-day lock up period with regard to ordinary shares acquired in the exchange offer.
Ms. Ting Zheng, Chairperson and CEO of China Cord Blood Corporation commented, "We believe shareholders will appreciate our simplified capital structure. With no further dilution, shareholders will fully enjoy the benefits of our operational accomplishments and robust growth, even on a per share basis. With all the stakeholders' interests now fully aligned, we will continue to expand our dominance within the China market, as well as the Asia Pacific region, to better capitalize on emerging opportunities."
Immediately after giving effect to the warrant exchange, China Cord Blood Corporation will have 75,406,868 ordinary shares issued and outstanding, and any remaining warrants outstanding that are not exercised will expire at 5:00 p.m. U.S. Eastern Time on the date of this press release.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Important Additional Information
This press release and the description contained herein are for informational purposes only and are not an offer to purchase or a solicitation of an offer to sell securities of the Company.
For more information, please contact:
China Cord Blood Corporation
Ms. Joeling Law Tel: (+852) 3605-8180 Email: ir@chinacordbloodcorp.com
ICR, LLC In New York: Ashley M. Ammon: 1-646-277-1227 In Beijing: Wen Lei Zheng: +86-10-6583-7510
China Cord Blood Corporation (NYSE: CO) ("CCBC" or "the Company") today announced its plan to release financial results for the third quarter and first nine months of fiscal year 2011 on Monday, February 28, 2011, after market close in the US.
The Company will hold a teleconference at 8:00 p.m. ET on Monday, February 28, 2011 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties may access the audio webcast through the following link: http://investor.chinacordbloodcorp.com/playerlink.zhtml?c=206671&s=wm&e=3696924. A replay of the webcast will be accessible two hours after the presentation and available for three weeks at the same URL link above. Listeners may also access the call by dialing 1-718-354-1231 or 1-866-519-4004 for US callers or +852-2475-0994 for Hong Kong callers, access code: 40003001.
Supplemental financial information referenced in the conference call and the text of the third quarter press release will be available at http://www.chinacordbloodcorp.com, in the section titled Investor Center/Press Release, after 4:30 p.m. ET on the day of the conference call.
Please dial in ten minutes prior to the conference to ensure proper connection and be prepared to provide your name and company to the operator.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood banking operator with multiple licenses. Under the current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and only seven licenses have been authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
For more information, please contact:
China Cord Blood Corporation Ms. Joeling Law Tel: +852-3605-8180 Email: ir@chinacordbloodcorp.com
ICR, LLC In New York: Ashley M. Ammon Tel: +1-646-277-1227 In Beijing: Wen Lei Zheng Tel: +86-10-6583-7510
News 
Market Data 
Discover 
